Edgewise Therapeutics (EWTX) Change in Accured Expenses (2020 - 2026)

Edgewise Therapeutics has disclosed Change in Accured Expenses across 7 years of filings, most recently posting $635000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $635000.0, up 420.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (up 108.9% YoY), and the FY2025 annual result was $2.4 million, up 105.01% from the prior year.
• Change in Accured Expenses came in at $635000.0 for Q1 2026 at Edgewise Therapeutics, down from $4.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.4 million in Q4 2025 to a low of -$2.0 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $635000.0 (2026), against an average of $415588.2.
• Across the five-year window, Change in Accured Expenses slumped 228.35% in 2024 and soared 564.47% in 2025, its largest moves.
• Edgewise Therapeutics' Change in Accured Expenses stood at $1.4 million in 2022, then climbed by 7.08% to $1.5 million in 2023, then tumbled by 56.32% to $667000.0 in 2024, then jumped by 564.47% to $4.4 million in 2025, then sank by 85.67% to $635000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $635000.0 (Q1 2026), $4.4 million (Q4 2025), and -$765000.0 (Q3 2025), per Business Quant data.